skip to main content

Prostate Cancer PSMA — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateUrological CancersProstate Cancer PSMASCE Medical Oncology

A 72-year-old man with metastatic castration-resistant prostate cancer asks about the PSMA-targeted radioligand therapy lutetium-177-PSMA-617. What was the key eligibility criterion in the VISION trial?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — PSMA-positive disease on 68Ga-PSMA PET-CT AND prior treatment with at least one ARPI and one taxane

The VISION trial demonstrated that 177Lu-PSMA-617 (plus standard care) significantly improved OS and rPFS compared with standard care alone in mCRPC patients who had PSMA-positive disease on PSMA-PET imaging AND had received prior ARPI and prior taxane chemotherapy. PSMA-PET positivity (at least one PSMA-positive metastatic lesion with no PSMA-negative dominant lesion) is a mandatory eligibility criterion. This represents a theranostic approach — using the same target for diagnosis (68Ga-PSMA PET) and therapy (177Lu-PSMA).

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer